What is Corcept Therapeutics Inc worth?
With the base-case assumptions below, a discounted cash flow model on Corcept Therapeutics Inc's reported free cash flow gives $39.97 per share. The share price was $116.10 on September 25, 2026, 190% above that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $24.65 | -79% |
| Base | 15.0% | 9.0% | $39.97 | -66% |
| Bull | 20.0% | 8.0% | $68.49 | -41% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $51.57 | $55.18 | $59.60 | $65.13 | $72.23 |
| 8.0% | $42.85 | $45.20 | $47.97 | $51.30 | $55.36 |
| 9.0% | $36.51 | $38.12 | $39.97 | $42.13 | $44.68 |
| 10.0% | $31.71 | $32.85 | $34.14 | $35.62 | $37.32 |
| 11.0% | $27.94 | $28.78 | $29.72 | $30.77 | $31.96 |
Where the presets come from
Base: years 1 to 5 grow at Corcept Therapeutics Inc's revenue growth rate over the last 5 fiscal years (16.6% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions